Consensus Biogen Inc. Xetra

Stocks

IDP

US09062X1037

Pharmaceuticals

Market Closed - Xetra 18:35:45 29/09/2026 +03			After hours 22:33:04
198.98 ^EUR	-1.37%		200.42	+0.73%

09-23	AI-based drug developer Basecamp valued at $800 million after $140 million funding round	RE
09-17	Biogen Publishes Phase 3 Pediatric EMPAVELI Data Showing Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3g or Primary IC-MPGN	CI

b141d1.BR1JYDASy7fvgXMamKoMcslKq2y3ARFfxmGaYCKa3nQ.MVIvNX9ro-aqzQUt_9M1F5867zP-b0My6wOiNmz_vS5ybgENBFeM4J_NGA~036c0c18d9545a3beabe551c81225629

Analysts' recommendations: Biogen Inc.

09-03	Piper Sander Adjusts Biogen Price Target to $245 From $225, Maintains Overweight Rating	MT
08-25	RBC Capital Adjusts Price Target on Biogen to $260 From $240, Keeps Outperform Rating	MT
08-25	RBC Adjusts Price Target on Biogen to $260 From $240, Maintains Outperform Rating	MT
08-25	RBC Capital Adjusts Price Target on Biogen to $260 From $240	MT
08-13	Wolfe Upgrades Biogen to Outperform From Peer Perform, Price Target is $300	MT
08-10	HSBC Adjusts Price Target on Biogen to $165 From $157, Keeps Reduce Rating	MT
08-03	Mizuho Adjusts Price Target on Biogen to $241 From $221	MT
07-30	BMO Capital Adjusts Price Target on Biogen to $208 From $196, Maintains Market Perform Rating	MT
07-30	TD Cowen Adjusts Price Target on Biogen to $225 From $215, Maintains Buy Rating	MT
07-30	Canaccord Genuity Adjusts Price Target on Biogen to $248 From $245, Maintains Buy Rating	MT
07-30	Goldman Sachs Adjusts Price Target on Biogen to $290 From $271, Maintains Buy Rating	MT
07-30	BMO Raises Price Target on Biogen to $208 From $196, Keeps Market Perform Rating	MT
07-30	UBS Adjusts Price Target on Biogen to $240 From $225, Maintains Buy Rating	MT
07-30	RBC Trims Price Target on Biogen to $240 From $242, Keeps Outperform Rating	MT
07-29	JPMorgan Lifts Biogen Price Target to $210 From $185	MT
07-29	Wedbush Adjusts Biogen Price Target to $215 From $201, Maintains Neutral Rating	MT
07-29	Stifel Nicolaus Adjusts Biogen Price Target to $242 From $214	MT
07-28	Barclays Adjusts Biogen Price Target to $200 From $185, Maintains Equalweight Rating	MT
07-24	Rothschild & Co Redburn Adjusts Price Target on Biogen to $210 From $190, Maintains Neutral Rating	MT
07-21	BofA Securities Adjusts Biogen Price Target to $215 From $217	MT
07-21	Guggenheim Adjusts Price Target on Biogen to $280 From $260, Maintains Buy Rating	MT
07-20	Goldman Sachs Adjusts Price Target on Biogen to $271 From $250, Maintains Buy Rating	MT
07-14	Cantor Fitzgerald Adjusts Biogen Price Target to $237 From $206	MT
07-13	Wedbush Raises Price Target on Biogen to $201 From $196, Keeps Neutral Rating	MT
07-13	Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth…

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	MODERNA, INC.					-39.4%
	REGENERON PHARMACEUTICALS, INC.					+13.11%
	CSL LIMITED					-0.53%
	UCB					+34.12%
	SAMSUNG BIOLOGICS CO.,LTD.					+40.9%
	BIOGEN INC.					+4.15%
	INCYTE CORPORATION					+2.51%
	INNOVENT BIOLOGICS, INC.					+34.31%
	SWEDISH ORPHAN BIOVITRUM AB					+14%
	Average					+11.46%
	Weighted average by Cap.					+6.23%